What RapidAI does

RapidAI (legal entity iSchemaView, Inc.) is a privately held clinical AI company that develops FDA-cleared imaging software for stroke, neurovascular, and cardiovascular care. Its Rapid Enterprise Platform bundles 30 cleared modules — including Rapid CTP, Rapid LVO/LMVO, Rapid ICH, Rapid Aneurysm, Rapid PE, Rapid Aortic, Rapid CT Stroke, Navigator Pro, Lumina 3D, AngioFlow, Rapid Insights, and the Rapid Mobile App — deployed via the Rapid Edge Cloud infrastructure. The technology processes CT and MRI imaging using proprietary algorithms and biomarkers such as the Hypoperfusion Intensity Ratio (HIR) and CBV Index to support patient selection for thrombectomy and thrombolysis, automated detection of hemorrhages and vessel occlusions, volumetric aneurysm monitoring, pulmonary embolism triage, and 3D vascular reconstruction, with claimed sensitivity/specificity metrics such as 97.84% sensitivity and 99.52% specificity for ICH detection and 94% sensitivity and 93% specificity for PE detection. The platform originated at Stanford University in 2008 and underpinned landmark stroke trials (DAWN, DEFUSE 3, SWIFT-PRIME, EXTEND-IA) that expanded the standard-of-care treatment window from 6 to 24 hours, and is cited as being backed by 750+ clinical publications, 11 NEJM papers, and 25+ clinical trials.

RapidAI monetizes its software through enterprise SaaS / Software-as-a-Medical-Device (SaMD) licensing sold via direct field sales to hospitals and health systems, with quote-based annual subscription pricing that is not publicly disclosed. It serves 2,500+ hospitals across 100+ countries, with named customers spanning the largest US health systems (HCA, Ascension, CommonSpirit, Providence, Trinity, Intermountain, Corewell, Tenet/Atrium) and academic medical centers (Cleveland Clinic, Stanford, Mayo Clinic, Johns Hopkins, UChicago Medicine), as well as international sites (Russells Hall, UK; India deployments). Reported clinical workflow outcomes include 33-52 minute reductions in door-to-treatment times for stroke, 92% reduction in unnecessary transfers, and customer-reported financial gains such as $2.6M in clinical AI value at OSF HealthCare. The company is HQ'd in San Mateo, California (data privacy office in Golden, CO), employs 101-250 staff, and is led by CEO Karim Karti (formerly President & CEO of GE Healthcare Imaging) with co-founders Greg Albers, MD (Stanford Stroke Center) and Roland Bammer, PhD (Stanford 3D Lab) on the scientific side.

The company has raised roughly $100M+ across disclosed funding activity, led by a $75M Series C from Vista Credit Partners in July 2023 with participation from TCV and Lennertz & Co. In 2025 it accelerated product velocity — launching Lumina 3D (TIME Best Inventions 2025), receiving five new FDA clearances (Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, Rapid Aortic), expanding its AWS partnership for global scaling of Rapid Edge Cloud, and announcing 28 ISC 2026 scientific abstracts. Earlier strategic moves included the June 2020 acquisition of EndoVantage (terms undisclosed) and the 2022 introduction of the first Edge Cloud platform and non-contrast CT imaging for ischemic stroke.

Name

RapidAI

Legal name

iSchemaView, Inc.

Website

https://rapidai.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

RapidAI is a privately held clinical AI company that develops FDA-cleared imaging software used by 2,500+ hospitals across 100+ countries to detect strokes, aneurysms, hemorrhages, pulmonary embolisms, and aortic disease, and to accelerate treatment decisions in time-critical neurovascular and cardiovascular care.

Ownership category

akta.pro rank

Product category

Clinical AI Imaging Software

NAICS

Software Publishers (513210)

SIC

Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Medical Imaging AI (HDAAAEAH)

akta.pro secondary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• Clinical AI imaging
• Stroke detection software
• Medical imaging analysis
• Neurovascular AI platform
• Radiology workflow software

Headquarters

HQ city

San Mateo

HQ country

United States

HQ region

North America

Offices2 records

Markets served

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software as a Medical Device (SaMD): Enterprise software licensing model for hospitals and healthcare systems. The platform is deployed across hospital networks with FDA-cleared imaging modules. Revenue generated through software licensing, implementation services, and ongoing support contracts with health systems.

Pricing tiers

Distribution channels2 records

Marketing channels8 records

Core offering

RapidAI develops and sells a deep clinical AI platform (Rapid Enterprise Platform) that processes CT, MRI, and CTA medical imaging to support clinical decision-making for stroke, aneurysm, pulmonary embolism, aortic disease, and radiology workflows. The platform consists of 30 FDA-cleared imaging modules licensed to hospitals and health systems under enterprise SaaS subscriptions, with implementation, support, and ongoing clinical services bundled into multi-year contracts.

Product overview

RapidAI offers a comprehensive deep clinical AI platform called the Rapid Enterprise Platform, which includes multiple FDA-cleared imaging modules and solutions for neurovascular, cardiac, and radiology care. The portfolio centers on the core platform augmented by specialized products including Lumina 3D (3D imaging reconstruction), Rapid Aneurysm (cerebral aneurysm detection), Rapid PE (pulmonary embolism), Rapid Aortic (aortic disease), Rapid LVO/LMVO (vessel occlusion detection), Rapid CT Stroke (ischemic stroke), Rapid ICH (hemorrhage detection), Navigator Pro (radiology workflow), Rapid Insights (analytics), and the Rapid Mobile App. The platform is powered by Rapid Edge Cloud infrastructure and supports 2,250+ hospitals across 100+ countries with 30 FDA-cleared modules.

Differentiator

Problem solved

Functional benefit

Brands

• Rapid Enterprise Platform: The cross-disciplinary deployment platform for deep clinical AI enabling disease state decision support across healthcare networks.
• Navigator Pro
• Lumina 3D
• Rapid Edge Cloud
• Rapid Mobile App
• Rapid Insights
• AngioFlow by RapidAI
• Rapid Aortic
• Rapid PE
• Rapid ICH
• Rapid LVO
• Rapid DeltaFuse
• Rapid LMVO
• Rapid MLS
• Rapid OH

Products and services

• Rapid Enterprise Platform Cross-disciplinary enterprise AI platform that connects intelligence, workflow, and teams across health systems, enabling deployment of deep clinical AI decision support across multiple disease states for hospitals and hospital networks.
• Lumina 3D AI-driven 3D imaging solution that automatically generates detailed 3D vascular views of the brain and neck from CT scans with vessel segmentation and automated bone removal, designed for radiologists and stroke care teams.
• Rapid Aneurysm AI-powered platform for cerebral aneurysm detection, volumetric measurement, and longitudinal monitoring, used by neurovascular and neurosurgery teams to detect clinically significant growth missed by traditional 2D methods.
• Rapid PE Pulmonary embolism AI solution for triage, RV/LV ratio assessment, and incidental PE detection, helping cardiology and pulmonary embolism teams identify treatment-eligible patients and coordinate care.
• Rapid Aortic FDA-cleared AI solution for aortic disease assessment and management that automatically analyzes CT scans, generates zonal maximums and landmark measurements, and supports longitudinal monitoring of aortic patients.
• Rapid LVO AI module for automated detection of large vessel occlusions (ICA, MCA) on CT angiography with high sensitivity and negative predictive value, used by stroke teams for rapid LVO identification.
• Rapid LMVO FDA-cleared imaging module that detects suspected vessel occlusions across ICA, MCA, ACA, Basilar, and PCA, providing complete visibility into vascular pathology beyond LVO-only detection.
• Rapid MLS FDA-cleared imaging module expanding clinical AI capabilities for stroke and brain injury diagnosis and treatment.
• Rapid OH FDA-cleared imaging module for detection and management of brain injury conditions including hydrocephalus.
• Rapid DeltaFuse FDA-cleared imaging module enhancing the Rapid Enterprise Platform with advanced clinical AI for improved decision-making and patient management.
• Rapid ICH AI-driven intracranial hemorrhage detection module with high sensitivity and specificity, used by radiology and stroke teams for automated cerebral hemorrhage identification.
• Rapid CTP CT perfusion analysis software using advanced biomarkers such as Hypoperfusion Intensity Ratio (HIR) and CBV Index for predicting collateral status and infarct growth, used for patient selection in thrombectomy and thrombolysis.
• Rapid CT Stroke Non-contrast CT imaging platform for ischemic stroke detection and assessment.
• Navigator Pro Imaging prioritization and AI decision support tool for radiology departments that helps triage and prioritize imaging worklists.
• Rapid Insights Custom performance analytics platform enabling tracking and analysis of imaging metrics, patient data, and operational efficiency for care teams.
• Rapid Mobile App Mobile application providing real-time collaboration, alerts for urgent cases, DICOM viewer access, team coordination, and EMR integration.
• Rapid Edge Cloud Enterprise infrastructure platform delivering speed, resilience, and security for AI deployment across the Rapid Enterprise Platform, supporting hospitals in over 100 countries through edge computing capabilities.
• AngioFlow AI-powered imaging solution for stroke care workflow optimization, deployed by hospital systems such as St. Luke's University Health Network.

Quantifiable outcome

• 92% reduction in unnecessary transfers
• +15 more outcomes

Named customers30 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability7 records

Feature11 records

Partnerships

Four partnerships are on record, tiered core.

• Amazon Web Services (AWS)coreTechnology or Integration · 1 December 2025Expanded partnership to accelerate global deployment and scalability of deep clinical AI in healthcare. Combines AWS's AI infrastructure and machine learning pipelines with RapidAI's deep clinical expertise and multimodal healthcare data. Rapid Edge Cloud platform currently supports hospitals in over 100 countries. Focus on co-development of advanced AI solutions to improve diagnostic precision, streamline clinical workflows, and expand access to life-saving technologies worldwide.
• Florida Stroke RegistrycoreStrategic or Co-development PartnerCollaboration across 190 stroke centers demonstrating the clinical and operational value of RapidAI's FDA-cleared deep clinical AI platform. Partnership supports real-world evidence generation and workflow optimization across the stroke care continuum.
• Stanford Stroke CentercoreStrategic or Co-development PartnerCo-founder Dr. Greg Albers serves as Director of Stanford Stroke Center since 1992. Research collaboration led to landmark trials (DAWN, DEFUSE 3) that changed global stroke guidelines. Stanford 3D Lab co-directed by co-founder Roland Bammer. Ongoing clinical validation partnership supporting publication of clinical evidence.
• NIH StrokeNetcoreStrategic or Co-development PartnerRapidAI serves as exclusive imaging vendor for SISTER Trial (Phase 2, prospective, randomized, placebo-controlled trial for TS23). Also used for patient selection in HI-PEITHO trial for pulmonary embolism treatment.

Scale indicators28 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Viz.ai: Viz.ai is the most direct competitor to RapidAI, offering AI-powered LVO/stroke detection, care coordination, and an enterprise platform deployed at hospitals. RapidAI explicitly benchmarks its Rapid LVO product against Viz LVO, underscoring head-to-head overlap in stroke imaging AI.
• Aidoc: Aidoc provides a broad AI imaging platform covering multiple pathologies (including stroke and PE) deployed at hospital systems. It competes directly with RapidAI's enterprise imaging AI strategy and cross-disease module approach.
• Brainomix: Brainomix provides AI-based stroke imaging assessment (e.g., e-ASPECTS), directly competing with RapidAI's CT perfusion and stroke triage modules in neurovascular workflows across US and European hospitals.

Emerging players

• Avicenna.AI: Avicenna.AI develops AI tools for emergency and neurovascular imaging, including stroke and PE detection workflows. It competes in the same hospital radiology and acute-care AI budgets as RapidAI but with a narrower product set.
• Annalise.ai: Annalise.ai offers comprehensive radiology AI covering chest, brain, and musculoskeletal imaging, competing for the same enterprise radiology decision-support budgets that RapidAI's Navigator Pro and Lumina 3D target.
• Nanox (Zebra Medical Vision): Nanox, which acquired Zebra Medical Vision, offers AI imaging analytics across multiple disease states and competes with RapidAI for hospital imaging AI contracts, particularly in cross-disease enterprise deployments.

Broad incumbents

• GE Healthcare: GE Healthcare is the broad incumbent from which RapidAI's CEO (Karim Karti) and CTO (Amit Phadnis, creator of Edison) hail. Its Edison platform and native AI capabilities across imaging modalities compete with RapidAI's enterprise platform, especially at IDN customers that already standardize on GE.
• Siemens Healthineers: Siemens Healthineers offers AI-Rad Companion and digital health solutions across its imaging equipment installed base. It competes with RapidAI by bundling AI capabilities into modality and PACS purchases rather than as a standalone enterprise software contract.
• Philips: Philips provides IntelliSpace AI and enterprise imaging informatics, competing with RapidAI's Rapid Enterprise Platform and Navigator Pro at hospitals standardizing on Philips PACS/RIS and modality infrastructure.

Others

• iSchemaView (acquired by RapidAI legacy entity): RapidAI is itself the rebranded iSchemaView, the original developer of the RAPID perfusion platform; included here as a historical reference rather than a separate peer.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/rapidai
• YouTubeyoutube.com/@rapidai6001
• LinkedInlinkedin.com/company/rapid-ai
• Facebookfacebook.com/rapidai

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RapidAI